DGCRF Diagnocure Inc (CE)

Transition plan in place

QUEBEC CITY, Oct. 1, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR)
(OTCQX: DGCRF) (the "Corporation") announced today that Ms. Chantal
Miklosi has resigned her position as Chief Financial Officer of the
Corporation effective October 11^th. She will leave to pursue other career opportunities. Dr. Yves Fradet,
President and Chief Medical Officer, supported by Mr. Richard
Bordeleau, Senior Advisor, will maintain contact with investors and the
general public. Mr. Frédéric Boivin, Senior Director, who has served in
finances and administration for 12 years, will oversee financial
matters. Ms. Danielle Allard, Senior Director, Corporate Affairs will
continue to be responsible for all filings to regulatory agencies.

Dr. Yves Fradet, President and Chief Medical Officer said, "I want to
thank Chantal for her important contributions to the Corporation during
her tenure as Chief Financial Officer. She played an instrumental role
in negotiating and closing all of DiagnoCure's recent business
arrangements. We wish Chantal well in her new endeavors. As
communicated recently, the DiagnoCure team will continue working on
short-term initiatives aimed at increasing shareholder value and
exploring all opportunities to enhance longer-term prospects for the
Corporation."

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. Previstage^TM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license on the diagnostic applications of its
proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate
cancer test is commercialized in Europe under CE mark and is approved
for commercialization in Canada and the United States. For more
information, please visit www.diagnocure.com.

Forward?looking statements

This release may contain forward?looking statements that involve known
and unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates", "assumes",
"believes", "estimates", "expects", "intend", "may", "plans",
"projects", "should", "will", or the negative thereof or other
variations thereon. Forward-looking statements also include any other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the "safe-harbour"
provisions of applicable Canadian securities laws. By their very
nature, forward?looking statements are based on expectations and
hypotheses and also involve risks and uncertainties, known and unknown,
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors and
others in understanding certain key elements of the Corporation's
current objectives, strategic priorities, expectations and plans, and
in obtaining a better understanding of the Corporation's business and
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes and that they
should not place undue reliance on these forward?looking statements.
For instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based on
management expectations and such outcome may vary materially depending
on global political and economic conditions, dependence on
collaboration partners, uncertainty of healthcare reimbursement, and
marketing and distribution challenges. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly update
or revise any forward?looking statements contained herein unless
required by the applicable securities laws and regulations.

SOURCE DiagnoCure inc.